Tuesday, 11 September 2012

Zovirax Double-Strength Suspension 100ml





Zovirax Double Strength Suspension



aciclovir




Read all of this leaflet carefully before you start taking this medicine.



  • Keep this leaflet. You may need to read it again.

  • If you have any further questions, ask your doctor or pharmacist.

  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.

  • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.




In this leaflet:



  • 1 What Zovirax is and what it is used for

  • 2 Before you take Zovirax

  • 3 How to take Zovirax

  • 4 Possible side effects

  • 5 How to store Zovirax

  • 6 Further information





What Zovirax is and what it is used for



Zovirax Double Strength Suspension (called ‘Zovirax’ in this leaflet) contains a medicine called aciclovir. This belongs to a group of medicines called antivirals. It works by killing or stopping the growth of viruses.



Zovirax can be used to:



  • treat chickenpox and shingles

  • treat cold sores and genital herpes

  • stop these problems returning after you have had them

  • stop these problems in people whose immune systems work less well, which means their bodies are less able to fight infections.




Before you take Zovirax




Do not use Zovirax if:



  • you are allergic (hypersensitive) to aciclovir or valaciclovir or any of the other ingredients (listed in Section 6).

Do not take Zovirax if the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking Zovirax.





Take special care with Zovirax



Check with your doctor or pharmacist before taking Zovirax if:



  • you have kidney problems

  • you are over 65 years of age.

If you are not sure if the above apply to you, talk to your doctor or pharmacist before taking Zovirax.





Taking other medicines



Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This includes medicines obtained without a prescription, including herbal medicines.



In particular tell your doctor or pharmacist if you are taking any of the following medicines:



  • probenecid, used to treat gout

  • cimetidine, used to treat stomach ulcers

  • mycophenolate mofetil, used to stop your body rejecting transplanted organs.




Pregnancy and breast-feeding



Ask your doctor or pharmacist for advice before using any medicine.






How to take Zovirax



Always take Zovirax exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.





Taking this medicine



  • Take this medicine by mouth.

  • Use the spoon provided to carefully measure the dose needed.

  • Start to take Zovirax as soon as possible.

The dose that you should take will depend on what you have been given Zovirax for. Your doctor will discuss this with you.





Treatment of chickenpox and shingles



  • The usual dose is two 5 ml spoonfuls five times a day.


  • You should space each dose by 4 hours. Suggested times are: 7am, 11am, 3pm, 7pm and 11pm.


  • You should take Zovirax for seven days.




Treatment of cold sores and genital herpes



  • The usual dose is one 2.5 ml spoonful five times a day.


  • You should space each dose by 4 hours. Suggested times are: 7am, 11am, 3pm, 7pm and 11pm.


  • You should take Zovirax for five days, or longer if your doctor tells you to.




Stopping these problems returning after you have had them



  • The usual dose is one 2.5 ml spoonful four times a day.

  • You should try to space each dose by 6 hours.

  • You should take Zovirax until your doctor tells you to stop.




Stopping these problems in people whose immune systems work less well and whose bodies are less able to fight infections



  • The usual dose is one 2.5 ml spoonful four times a day.

  • You should try to space each dose by 6 hours.

  • You should take Zovirax until your doctor tells you to stop.




Your doctor may adjust the dose of Zovirax if:



  • it is for a child

  • you are over 65 years of age

  • you have kidney problems. If you have kidney problems, it is important to drink plenty of water while you are being treated with Zovirax.

Talk to your doctor before taking Zovirax if any of the above apply.





If you take more Zovirax than you should



Zovirax is not usually harmful, unless you take too much over several days. Talk to your doctor or pharmacist if you take too much Zovirax. Take the medicine pack with you.





If you forget to take Zovirax



  • If you forget to take Zovirax, take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose.


  • Do not take a double dose to make up for a forgotten dose.





Possible side effects



Like all medicines, Zovirax can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:




Allergic reactions (affects less than 1 in 1,000 people)



If you have an allergic reaction, stop taking Zovirax and see a doctor straight away. The signs may include:



  • rash, itching or hives on your skin

  • swelling of your face, lips, tongue or other parts of your body

  • shortness of breath, wheezing or trouble breathing

  • unexplained fever (high temperature) and feeling faint, especially when standing up.




Other side effects include:



Common (affects less than 1 in 10 people)



  • headache

  • feeling dizzy

  • feeling or being sick

  • diarrhoea

  • stomach pains

  • rash

  • skin reaction after exposure to light (photosensitivity)

  • itching

  • feeling tired

  • fever.

Uncommon (affects less than 1 in 100 people)



  • itchy, hive-like rash

  • hair loss.

Rare (affects less than 1 in 1,000 people)



  • difficulty breathing

  • effects on some blood and urine tests

  • swelling of your face, lips, mouth, tongue or throat.

Very rare (affects less than 1 in 10,000 people)



  • nosebleeds and bruising more easily than usual

  • feeling weak

  • feeling agitated or confused

  • shaking or tremors

  • hallucinations (seeing or hearing things that aren’t there)

  • fits

  • feeling unusually sleepy or drowsy

  • unsteadiness when walking and lack of coordination

  • difficulty speaking

  • inability to think or judge clearly

  • unconsciousness (coma)

  • paralysis of part or all of your body

  • disturbances of behaviour, speech and eye movements

  • stiff neck and sensitivity to light

  • inflammation of the liver (hepatitis)

  • yellowing of your skin and whites of your eyes (jaundice)

  • kidney problems where you pass little or no urine

  • pain in your lower back, the kidney area of your back or just above your hip (renal pain).



If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.





How to store Zovirax



  • Keep out of the reach and sight of children.

  • Do not store above 30°C.

  • Do not use Zovirax after the expiry date which is stated on the carton. The expiry date (Exp.) refers to the last day of that month.

  • Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.




Further information




What Zovirax Double Strength Suspension contains



  • The active substance is aciclovir.

  • The other ingredients are sorbitol solution, glycerol, dispersible cellulose, methyl parahydroxybenzoate, propyl parahydroxybenzoate, orange flavour and purified water.




What Zovirax looks like and contents of the pack



Zovirax Double Strength Suspension is supplied to you in an amber-coloured glass bottle, containing 100 ml of an off-white suspension. The medicine comes with a double-ended measuring spoon. One end of the spoon will give you 5 ml of the suspension and the other will give you 2.5 ml.



Each 5 ml of Zovirax Double Strength Suspension contains 400 mg aciclovir.





Marketing authorisation holder and manufacturer



Marketing authorisation holder




GlaxoSmithKline UK

Stockley Park West

Uxbridge

Middlesex

UB11 1BT



Manufacturer




Glaxo Wellcome GmbH & Co. KG

Industriestrasse 32-36

23843 Bad Oldesloe

Germany





Other formats:



To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge:



0800 198 5000 (UK Only)




Please be ready to give the following information:



Product name: Zovirax Double Strength Suspension



Reference number: 00003/0264



This is a service provided by the Royal National Institute of the Blind.



Leaflet date: July 2008



Zovirax is a registered trademark of the GlaxoSmithKline group of companies.



© 2008 GlaxoSmithKline group of companies






10000000050985






Monday, 10 September 2012

Erythrocin 500 Tablets





1. Name Of The Medicinal Product



Erythrocin 500


2. Qualitative And Quantitative Composition









 

 

mg / tablet

Active:

Erythromycin as erythromycin stearate

500


3. Pharmaceutical Form



Film coated tablet



4. Clinical Particulars



4.1 Therapeutic Indications



For the prophylaxis and treatment of infections caused by erythromycin-sensitive organisms.



Erythromycin is highly effective in the treatment of a great variety of clinical infections such as:



1. Upper Respiratory Tract infections: tonsillitis, peritonsillar abscess, pharyngitis, laryngitis, sinusitis, secondary infections in influenza and common colds



2. Lower Respiratory Tract infections: tracheitis, acute and chronic bronchitis, pneumonia (lobar pneumonia, bronchopneumonia, primary atypical pneumonia), bronchiectasis, Legionnaire's disease



3. Ear infection: otitis media and otitis externa, mastoiditis



4. Oral infections: gingivitis, Vincent's angina



5. Eye infections: blepharitis



6. Skin and soft tissue infections: boils and carbuncles, paronychia, abscesses, pustular acne, impetigo, cellulitis, erysipelas



7. Gastrointestinal infections: cholecystitis, staphylococcal enterocolitis



8. Prophylaxis: pre- and post- operative trauma, burns, rheumatic fever



9. Other infections: osteomyelitis, urethritis, gonorrhoea, syphilis, lymphogranuloma venereum, diphtheria, prostatitis, scarlet fever



4.2 Posology And Method Of Administration



For oral administration



Adults and children over 8 years: For mild to moderate infections 2g daily in divided doses. Up to 4g daily in severe infections.



Elderly: No special dosage recommendations.



Note: For younger children, infants and babies, Erythroped, erythromycin ethylsuccinate suspensions, are normally recommended. The recommended dose for children age 2-8 years, for mild to moderate infections, is 1 gram daily in divided doses. The recommended dose for infants and babies, for mild to moderate infections, is 500 mg daily in divided doses. For severe infections doses may be doubled.



4.3 Contraindications



Known hypersensitivity to erythromycin.



Erythromycin is contraindicated in patients taking astemizole, terfenadine, cisapride or pimozide.



Erythromycin is contraindicated with ergotamine and dihydroergotamine.



4.4 Special Warnings And Precautions For Use



Erythromycin is excreted principally by the liver, so caution should be exercised in administering the antibiotic to patients with impaired hepatic function or concomitantly receiving potentially hepatotoxic agents. Hepatic dysfunction including increased liver enzymes and/or cholestatic hepatitis, with or without jaundice, has been infrequently reported with erythromycin.



Pseudomembranous colitis has been reported with nearly all antibacterial agents, including macrolides, and may range in severity from mild to life-threatening (see section.4.8). Clostridium difficile-associated diarrhoea (CDAD) has been reported with use of nearly all antibacterial agents including erythromycin, and may range in severity from mild diarrhoea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, which may lead to overgrowth of C. difficile. CDAD must be considered in all patients who present with diarrhoea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.



There have been reports suggesting erythromycin does not reach the foetus in adequate concentrations to prevent congenital syphilis. Infants born to women treated during pregnancy with oral erythromycin for early syphilis should be treated with an appropriate penicillin regimen.



There have been reports that erythromycin may aggravate the weakness of patients with myasthenia gravis.



Erythromycin interferes with the fluorometric determination of urinary catecholamines.



Rhabdomyolysis with or without renal impairment has been reported in seriously ill patients receiving erythromycin concomitantly with statins.



There have been reports of infantile hypertrophic pyloric stenosis (IHPS) occurring in infants following erythromycin therapy. In one cohort of 157 newborns who were given erythromycin for pertussis prophylaxis, seven neonates (5%) developed symptoms of non-bilious vomiting or irritability with feeding and were subsequently diagnosed as having IHPS requiring surgical pyloromyotomy. Since erythromycin may be used in the treatment of conditions in infants which are associated with significant mortality or morbidity (such as pertussis or chlamydia), the benefit of erythromycin therapy needs to be weighed against the potential risk of developing IHPS. Parents should be informed to contact their physician if vomiting or irritability with feeding occurs.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Increases in serum concentrations of the following drugs metabolised by the cytochrome P450 system may occur when administered concurrently with erythromycin: acenocoumarol, alfentanil, astemizole, bromocriptine, carbamazepine, cilostazol, cyclosporin, digoxin, dihydroergotamine, disopyramide, ergotamine, hexobarbitone, methylprednisolone, midazolam, omeprazole, phenytoin, quinidine, rifabutin, sildenafil, tacrolimus, terfenadine, theophylline, triazolam, valproate, vinblastine, and antifungals e.g fluconazole, ketoconazole and itraconazole. Appropriate monitoring should be undertaken and dosage should be adjusted as necessary. Particular care should be taken with medications known to prolong the QTc interval of the electrocardiogram.



Drugs that induce CYP3A4 (such as rifampicin, phenytoin, carbamazepine, phenobarbital, St John's Wort) may induce the metabolism of erythromycin. This may lead to sub-therapeutic levels of erythromycin and a decreased effect. The induction decreases gradually during two weeks after discontinued treatment with CYP3A4 inducers. Erythromycin should not be used during and two weeks after treatment with CYP3A4 inducers.



HMG-CoA Reductase Inhibitors: erythromycin has been reported to increase concentrations of HMG-CoA reductase inhibitors (e.g. lovastatin and simvastatin). Rare reports of rhabdomyolysis have been reported in patients taking these drugs concomitantly.



Contraceptives: some antibiotics may in rare cases decrease the effect of contraceptive pills by interfering with the bacterial hydrolysis of steroid conjugates in the intestine and thereby reabsorption of unconjugated steroid. As a result of this plasma levels of active steroid may decrease.



Antihistamine H1 antagonists: care should be taken in the coadministration of erythromycin with H1 antagonists such as terfenadine, astemizole and mizolastine due to the alteration of their metabolism by erythromycin.



Erythromycin significantly alters the metabolism of terfenadine, astemizole and pimozide when taken concomitantly. Rare cases of serious, potentially fatal, cardiovascular events including cardiac arrest, torsade de pointes and other ventricular arrhythmias have been observed (see sections 4.3 and 4.8).



Anti-bacterial agents: an in vitro antagonism exists between erythromycin and the bactericidal beta-lactam antibiotics (e.g. penicillin, cephalosporin). Erythromycin antagonises the action of clindamycin, lincomycin and chloramphenicol. The same applies for streptomycin, tetracyclines and colistin.



Protease inhibitors: in concomitant administration of erythromycin and protease inhibitors, an inhibition of the decomposition of erythromycin has been observed.



Oral anticoagulants: there have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants (e.g. warfarin) are used concomitantly.



Triazolobenzodiazepines (such as triazolam and alprazolam) and related benzodiazepines: erythromycin has been reported to decrease the clearance of triazolam, midazolam, and related benzodiazepines, and thus may increase the pharmacological effect of these benzodiazepines.



Post-marketing reports indicate that co-administration of erythromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterised by vasospasm and ischaemia of the central nervous system, extremities and other tissues (see section 4.3).



Elevated cisapride levels have been reported in patients receiving erythromycin and cisapride concomitantly. This may result in QTc prolongation and cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation and torsades de pointes. Similar effects have been observed with concomitant administration of pimozide and clarithromycin, another macrolide antibiotic.



Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity. In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy. There have been published reports suggesting when oral erythromycin is given concurrently with theophylline there is a significant decrease in erythromycin serum concentrations. This decrease could result in sub-therapeutic concentrations of erythromycin.



There have been post-marketing reports of colchicine toxicity with concomitant use of erythromycin and colchicine.



Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent verapamil, a calcium channel blocker.



Cimetidine may inhibit the metabolism of erythromycin which may lead to an increased plasma concentration.



Erythromycin has been reported to decrease the clearance of zopiclone and thus may increase the pharmacodynamic effects of this drug.



4.6 Pregnancy And Lactation



There are no adequate and well-controlled studies in pregnant women. However, observational studies in humans have reported cardiovascular malformations after exposure to medicinal products containing erythromycin during early pregnancy.



Erythromycin has been reported to cross the placental barrier in humans, but foetal plasma levels are generally low.



Erythromycin is excreted in breast milk, therefore, caution should be exercised when erythromycin is administered to a nursing mother.



4.7 Effects On Ability To Drive And Use Machines



None reported



4.8 Undesirable Effects



Blood and lymphatic system disorders:



Eosinophilia.



Cardiac disorders



QTc interval prolongation, torsades de pointes, palpitations, and cardiac rhythm disorders including ventricular tachyarrhythmias.



Ear and labyrinth disorders



Deafness, tinnitus



There have been isolated reports of reversible hearing loss occurring chiefly in patients with renal insufficiency or high doses.



Gastrointestinal disorders



The most frequent side effects of oral erythromycin preparations are gastrointestinal and are dose-related. The following have been reported:



upper abdominal discomfort, nausea, vomiting, diarrhoea, pancreatitis, anorexia, infantile hypertrophic pyloric stenosis.



Pseudomembranous colitis has been rarely reported in association with erythromycin therapy (see section 4.4).



General disorders and administration site conditions



Chest pain, fever, malaise.



Hepatobiliary disorders



Cholestatic hepatitis, jaundice, hepatic disfunction, hepatomegaly, hepatic failure, hepatocellular hepatitis (see section 4.4).



Immune system disorders



Allergic reactions ranging from urticaria and mild skin eruptions to anaphylaxis have occurred.



Investigations



Increased liver enzyme values.



Nervous system disorders



There have been isolated reports of transient central nervous system side effects including confusion, seizures and vertigo; however, a cause and effect relationship has not been established.



Psychiatric disorders



Hallucinations



Renal and urinary disorders



Interstitial nephritis



Skin and subcutaneous tissue disorders



Skin eruptions, prurituls, urticaria, exanthema, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme.



Vascular disorders



Hypotension.



4.9 Overdose



Symptoms: hearing loss, severe nausea, vomiting and diarrhoea.



Treatment: gastric lavage, general supportive measures.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



ATC code: J01FA01



Erythromycin exerts its antimicrobial action by binding to the 50S ribosomal sub-unit of susceptible microorganisms and suppresses protein synthesis. Erythromycin is usually active against most strains of the following organisms both in vitro and in clinical infections:



Gram positive bacteria - Listeria monocytogenes, Corynebacterium diphtheriae (as an adjunct to antitoxin), Staphylococci spp, Streptococci spp (including Enterococci).



Gram negative bacteria - Haemophilus influenzae, Neisseria meningitidis, Neisseria gonorrhoeae, Legionella pneumophila, Moraxella (Branhamella) catarrhalis, Bordetella pertussis, Campylobacter spp.



Mycoplasma - Mycoplasma pneumoniae, Ureaplasma urealyticum.



Other organisms - Treponema pallidum, Chlamydia spp, Clostridia spp, L-forms, the agents causing trachoma and lymphogranuloma venereum.



Note: The majority of strains of Haemophilus influenzae are susceptible to the concentrations reached after ordinary doses.



5.2 Pharmacokinetic Properties



Peak blood levels normally occur within one hour of dosing of erythromycin ethylsuccinate granules. The elimination half life is approximately two hours. Doses may be administered two, three or four times a day.



Erythromycin ethylsuccinate is less susceptible than erythromycin to the adverse effect of gastric acid. It is absorbed from the small intestine. It is widely distributed throughout body tissues. Little metabolism occurs and only about 5% is excreted in the urine. It is excreted principally by the liver.



5.3 Preclinical Safety Data



There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Povidone



Maize starch



Magnesium hydroxide



Polacrilin potassium



Polyethylene glycol 8000



Polyethylene glycol 400



Hydroxypropyl methyl cellulose



Sorbic acid.



6.2 Incompatibilities



None stated.



6.3 Shelf Life



60 months.



6.4 Special Precautions For Storage



None stated.



6.5 Nature And Contents Of Container



High density polyethylene bottle with urea cap with 100 tablets, securitainer or snap-secure container with 50, 100 or 1000 tablets. Blister packs containing 28 tablets: PVC, heat sealed with 20 micron hard tamper aluminium foil.



6.6 Special Precautions For Disposal And Other Handling



Not applicable



7. Marketing Authorisation Holder



Amdipharm plc



Regency House



Miles Gray Road



Basildon



Essex



SS14 3AF



8. Marketing Authorisation Number(S)



PL 20072/0037



9. Date Of First Authorisation/Renewal Of The Authorisation



16/06/97



10. Date Of Revision Of The Text



October 2010



11. LEGAL CATEGORY


POM




Saturday, 8 September 2012

Kytril Solution


Pronunciation: gra-NIS-e-tron
Generic Name: Granisetron
Brand Name: Kytril


Kytril Solution is used for:

Preventing nausea and vomiting caused by cancer chemotherapy and radiation. It may also be used for other conditions as determined by your doctor.


Kytril Solution is a 5-HT3 receptor antagonist. It works by blocking a chemical called serotonin that can cause vomiting.


Do NOT use Kytril Solution if:


  • you are allergic to any ingredient in Kytril Solution

  • you are taking apomorphine

Contact your doctor or health care provider right away if any of these apply to you.



Before using Kytril Solution:


Some medical conditions may interact with Kytril Solution. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you are allergic to other 5-HT3 receptor antagonists (eg, ondansetron)

  • if you have heart problems (eg, irregular heartbeat, conduction problems), blood electrolyte problems (eg, low calcium, potassium or magnesium), an abnormal electrocardiogram (ECG), or you are receiving chemotherapy that may cause heart problems

  • if you have stomach or bowel problems (eg, pain, swelling) or if you have recently had stomach surgery

Some MEDICINES MAY INTERACT with Kytril Solution. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Apomorphine because the risk of side effects, such as severely low blood pressure or loss of consciousness, may occur

  • Medicines that may affect your heartbeat, such as antiarrhythmics (eg, flecainide, sotalol), azole antifungals (eg, ketoconazole), or quinolones (eg, ciprofloxacin), because heart rhythm problems may occur. Ask your doctor if you are unsure if any medicines that you take may affect your heartbeat

This may not be a complete list of all interactions that may occur. Ask your health care provider if Kytril Solution may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Kytril Solution:


Use Kytril Solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Kytril Solution by mouth with or without food.

  • Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.

  • Use Kytril Solution only on the days that you receive your cancer treatment, unless otherwise directed by your doctor.

  • If you miss a dose of Kytril Solution, contact your doctor right away.

Ask your health care provider any questions you may have about how to use Kytril Solution.



Important safety information:


  • Kytril Solution may cause drowsiness or dizziness. These effects may be worse if you take it with alcohol or certain medicines. Use Kytril Solution with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Use Kytril Solution with extreme caution in CHILDREN. Safety and effectiveness have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Kytril Solution while you are pregnant. It is not known if Kytril Solution is found in breast milk. If you are or will be breast-feeding while you use Kytril Solution, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Kytril Solution:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Agitation; anxiety; constipation; diarrhea; dizziness; drowsiness; headache; indigestion; nausea; stomach pain; taste changes; trouble sleeping; vomiting; weakness.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; fainting; fast or irregular heartbeat; fever, chills, or sore throat; unusual muscle movement.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Kytril side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include headache.


Proper storage of Kytril Solution:

Store Kytril Solution at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Kytril Solution out of the reach of children and away from pets.


General information:


  • If you have any questions about Kytril Solution, please talk with your doctor, pharmacist, or other health care provider.

  • Kytril Solution is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Kytril Solution. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Kytril resources


  • Kytril Side Effects (in more detail)
  • Kytril Use in Pregnancy & Breastfeeding
  • Drug Images
  • Kytril Drug Interactions
  • Kytril Support Group
  • 2 Reviews for Kytril - Add your own review/rating


Compare Kytril with other medications


  • Nausea/Vomiting, Chemotherapy Induced
  • Nausea/Vomiting, Postoperative
  • Nausea/Vomiting, Radiation Induced

Friday, 7 September 2012

Isoniazid/Rifampin


Pronunciation: EYE-soe-NYE-a-zid/rif-AM-pin
Generic Name: Isoniazid/Rifampin
Brand Name: Examples include Rifamate and Isonarif

Isoniazid/Rifampin may cause severe and sometimes fatal liver problems (eg, hepatitis). The risk of liver problems is greater in patients over 35 years old. It may also be increased by daily use of alcohol, long-term liver problems, or unsanitary injectable drug use. Women, especially those who are black, are Hispanic, or have just had a baby, may also be at increased risk. Hepatitis can develop at any time during treatment, but usually occurs during the first 3 months. Your doctor will monitor your liver function and discuss your progress every month.


Contact your doctor right away if you develop unusual fatigue, weakness or fever that lasts longer than 3 days, general feeling of discomfort, loss of appetite, nausea, vomiting, numbness or tingling of the hands or feet, dark urine, yellowing of the skin or eyes, or stomach pain or tenderness.


Patients with active liver problems should not use Isoniazid/Rifampin.





Isoniazid/Rifampin is used for:

Treating tuberculosis (TB) of the lungs.


Isoniazid/Rifampin is a combination of 2 antibacterial agents. It works by killing TB bacteria.


Do NOT use Isoniazid/Rifampin if:


  • you are allergic to any ingredient in Isoniazid/Rifampin or to any rifamycin (eg, rifabutin)

  • you have had severe side effects from isoniazid, such as drug fever, chills, or arthritis

  • you have severe liver damage, active liver disease, or liver damage from previous use of Isoniazid/Rifampin

  • you have a history of hepatitis caused by any medicine

  • you are taking atazanavir, cabazitaxel, darunavir, delavirdine, dronedarone, etravirine, fosamprenavir, lurasidone, nifedipine praziquantel, ranolazine, saquinavir, tipranavir, a tyrosine kinase receptor inhibitor (eg, lapatinib), or voriconazole

Contact your doctor or health care provider right away if any of these apply to you.



Before using Isoniazid/Rifampin:


Some medical conditions may interact with Isoniazid/Rifampin. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have diabetes, the blood disease porphyria, kidney problems, nerve problems (eg, neuropathy) or risk of nerve problems, HIV, severe diarrhea due to antibiotic use (pseudomembranous colitis), or a history of liver problems or gout

  • if you have a history of alcohol or other substance abuse, have unsanitary injectable drug habits, or drink alcohol daily

  • if you are over 35 years old, you have recently given birth, or you have previously taken Isoniazid/Rifampin

  • if you wear contact lenses

Some MEDICINES MAY INTERACT with Isoniazid/Rifampin. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Atazanavir, cabazitaxel, darunavir, delavirdine, dronedarone, etravirine, fosamprenavir, lurasidone, nifedipine, praziquantel, ranolazine, saquinavir, tipranavir, tyrosine kinase receptor inhibitors (eg, lapatinib), or voriconazole because their effectiveness may be decreased by Isoniazid/Rifampin

  • Many prescription and nonprescription medicines (eg, used for alcoholism, asthma, cancer, infections, inflammation, aches and pains, heart problems, high blood pressure, high blood iron levels, high cholesterol, blood thinning, birth control, diabetes, HIV, hormone replacement, immune system suppression, irregular heartbeat, low sodium levels, low vitamin D levels, mental or mood problems, nausea and vomiting, Parkinson disease, seizures, sleep, thyroid) may interact with Isoniazid/Rifampin, increasing the risk of side effects or decreasing effectiveness.

This may not be a complete list of all interactions that may occur. Ask your health care provider if Isoniazid/Rifampin may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Isoniazid/Rifampin:


Use Isoniazid/Rifampin as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Isoniazid/Rifampin by mouth on an empty stomach at least 1 hour before or 2 hours after eating.

  • If you also take an antacid, take Isoniazid/Rifampin at least 1 hour before you take the antacid.

  • If you also take aminosalicylic acid granules, do not take it within 8 to 12 hours of Isoniazid/Rifampin. Check with your doctor if you have questions.

  • Continue to take Isoniazid/Rifampin even if you feel well. Do not miss any doses.

  • Do not stop taking Isoniazid/Rifampin without checking with your doctor. Rarely, kidney problems have occurred when patients started taking Isoniazid/Rifampin again after therapy was interrupted.

  • If you miss a dose of Isoniazid/Rifampin, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Isoniazid/Rifampin.



Important safety information:


  • Isoniazid/Rifampin may cause drowsiness or dizziness. These effects may be worse if you take it with alcohol or certain medicines. Use Isoniazid/Rifampin with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Check with your doctor before drinking alcohol while taking Isoniazid/Rifampin. Alcohol may increase the risk of liver problems. If you have a history of alcohol abuse, you may also be at increased risk of developing nerve problems from Isoniazid/Rifampin. Notify your doctor if you notice any unusual tingling in your hands or feet.

  • If you have a history of diabetes, alcohol abuse, or poor nutrition, your doctor may recommend that you also take vitamin B6 while you are taking Isoniazid/Rifampin. This may help to decrease your risk of nerve problems. Discuss any questions with your doctor.

  • Isoniazid/Rifampin may cause a reddish orange color of urine, stools, saliva, tears, sweat, sputum, and skin. This is normal and not a cause for concern.

  • Isoniazid/Rifampin may cause a permanent reddish orange color of soft contact lenses.

  • Eating foods high in tyramine (eg, aged cheeses, red wines, beer, certain meats and sausages, liver, sour cream, soy sauce, raisins, bananas, avocados) while you use Isoniazid/Rifampin may cause severe high blood pressure. Do not eat foods high in tyramine while you take Isoniazid/Rifampin. Seek medical attention at once if symptoms of severe high blood pressure occur. These may include severe headache, fast or irregular heartbeat, sore or stiff neck, nausea, vomiting, sweating, enlarged pupils, or sensitivity to light.

  • Do not eat foods high in histamine while you take Isoniazid/Rifampin. Eating foods high in histamine (eg, skipjack, tuna, tropical fish) while you use Isoniazid/Rifampin may cause low blood pressure, irregular heartbeat, headache, sweating, or flushing. Contact your doctor at once if any of these symptoms occur.

  • Ask your health care provider for a complete list of foods you should avoid while you are taking Isoniazid/Rifampin.

  • Hormonal birth control (eg, birth control pills, implants, patches) may not work as well while you are using Isoniazid/Rifampin. To prevent pregnancy, use an extra form of birth control (eg, condoms).

  • Isoniazid/Rifampin only works against TB bacteria; it does not treat viral infections (eg, the common cold).

  • Be sure to take Isoniazid/Rifampin for the full course of treatment. If you do not, the medicine may not clear up your infection completely. The bacteria could also become less sensitive to this or other medicines. This could make the infection harder to treat in the future.

  • Mild diarrhea is common with antibiotic use. However, a more serious form of diarrhea (pseudomembranous colitis) may rarely occur. This may develop while you take the antibiotic or within several months after you stop taking it. Contact your doctor right away if stomach pain or cramps, severe diarrhea, or bloody stools occurs. Do not treat diarrhea without first checking with your doctor.

  • Tell your doctor or dentist that you take Isoniazid/Rifampin before you receive any medical or dental care, emergency care, or surgery.

  • Diabetes patients - Isoniazid/Rifampin may affect your blood sugar. Check blood sugar levels closely. Ask your doctor before you change the dose of your diabetes medicine. You may also be at increased risk of developing nerve problems from Isoniazid/Rifampin. Contact your doctor if you notice any unusual tingling in your hands or feet.

  • Isoniazid/Rifampin may interfere with certain lab tests. Be sure your doctor and lab personnel know you are taking Isoniazid/Rifampin.

  • Lab tests, including complete blood cell counts, platelet counts, uric acid levels, kidney and liver function, and eye exams, may be performed while you take Isoniazid/Rifampin. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Use Isoniazid/Rifampin with caution in BLACK and HISPANIC WOMEN; they may have a greater risk of severe liver problems from Isoniazid/Rifampin.

  • Use Isoniazid/Rifampin with caution in patients over 35 years old; they may have a greater risk of severe liver problems from Isoniazid/Rifampin.

  • Isoniazid/Rifampin should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of taking Isoniazid/Rifampin while you are pregnant. Isoniazid/Rifampin is found in breast milk. If you are or will be breast-feeding while you take Isoniazid/Rifampin, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Isoniazid/Rifampin:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Diarrhea; dizziness; drowsiness; gas; headache; heartburn; mild stomach upset or cramps; nausea; trouble sleeping.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bloody or dark urine; change in the amount of urine produced; changes in vision; dark, tarry, or bloody stools; fever, chills, or sore throat; general feeling of discomfort; increased thirst or urination; joint pain or swelling; loss of appetite; memory problems; menstrual changes; mental or mood changes; muscle pain or weakness; seizures; severe diarrhea, nausea, or stomach cramps; shortness of breath; stomach pain or tenderness; swelling of the hands or legs; symptoms of low vitamin B6 levels (eg, confusion, cracks in the corners of the mouth, irritability, mouth redness or soreness, scaly rash); tingling or numbness in the hands or feet; unusual bruising or bleeding; unusual tiredness or weakness; vomiting; yellowing of the skin or eyes.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Isoniazid/Rifampin side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; hallucinations; loss of consciousness; seizures; severe dizziness or nausea; sluggishness; slurred speech; stomach pain or tenderness; symptoms of high blood sugar (eg, confusion, increased thirst or urination, rapid breathing, unusual drowsiness); very slow breathing; vomiting; yellowing of the skin or eyes.


Proper storage of Isoniazid/Rifampin:

Store Isoniazid/Rifampin between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Isoniazid/Rifampin out of the reach of children and away from pets.


General information:


  • If you have any questions about Isoniazid/Rifampin, please talk with your doctor, pharmacist, or other health care provider.

  • Isoniazid/Rifampin is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Isoniazid/Rifampin. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Isoniazid/Rifampin resources


  • Isoniazid/Rifampin Side Effects (in more detail)
  • Isoniazid/Rifampin Dosage
  • Isoniazid/Rifampin Use in Pregnancy & Breastfeeding
  • Isoniazid/Rifampin Drug Interactions
  • Isoniazid/Rifampin Support Group
  • 0 Reviews for Isoniazid/Rifampin - Add your own review/rating


Compare Isoniazid/Rifampin with other medications


  • Tuberculosis, Active

Thursday, 6 September 2012

Midazolam Hydrochloride



Class: Benzodiazepines
VA Class: CN302
Chemical Name: 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine monohydrochloride
Molecular Formula: C18H13ClFN3•HCl
CAS Number: 59467-96-8



  • Use only when adequate treatment facilities for appropriate management of therapy and complications are available.1 250




  • For deeply sedated pediatric patients, an individual other than the clinician performing the procedure should be dedicated to monitoring the patient throughout the procedure.1 250



  • Respiratory Effects


  • Associated with respiratory depression and respiratory arrest, especially when used for sedation in non-critical-care settings.1 250 (See Respiratory and Cardiovascular Effects under Cautions.)




  • Death or hypoxic encephalopathy has resulted when respiratory depression was not recognized promptly and treated effectively.1 250



  • Dosage and Administration Considerations for Procedural Sedation


  • Initial IV dose for healthy adults should not exceed 2.5 mg.1 250 (See Dosage under Dosage and Administration.)




  • Lower dosages are necessary in patients >60 years of age, debilitated patients, and patients receiving concomitant opiates or other CNS depressants.1 250 (See Dosage and also Special Populations, under Dosage and Administration.)




  • Titrate initial and subsequent dosages slowly; administer the appropriate dose over ≥2 minutes and wait an additional 2 or more minutes to fully evaluate the sedative effect.1




  • Administer by direct IV injection as the 1-mg/mL solution or dilute the 1- or 5-mg/mL solution to facilitate slower administration.1



  • Pediatric Dosage and Administration Considerations


  • Calculate pediatric dosage on a mg/kg basis.1 Initial dose is dependent on age, procedure, and route; titrate subsequent dosages slowly.1 (See Dosage: Pediatric Patients, under Dosage and Administration.)




  • Do not administer by rapid IV injection in neonates.1 Severe hypotension and seizures have been reported following rapid IV administration, particularly with concomitant administration of fentanyl.1




Introduction

Benzodiazepine;2 3 4 5 6 7 17 157 sedative, anxiolytic, amnesic,1 3 157 219 and hypnotic.2 4 7 70 84 86 104 177 178


Uses for Midazolam Hydrochloride


Preoperative Sedation, Anxiolysis, and Anterograde Amnesia


Preoperatively, to produce sedation, relieve anxiety, and provide anterograde amnesia.1 3 157 219


Some clinicians consider midazolam the benzodiazepine of choice for preoperative use for short surgical procedures because of its relatively rapid onset and short duration of effect and improved local tolerance at the site of injection compared with other currently available parenteral benzodiazepines.2 4 7 14 32 173 174 181


Procedural Sedation


For procedural sedation, anxiolysis, and amnesia (alone or in combination with an opiate agonist)1 3 157 when administered prior to dental2 4 7 14 35 66 130 131 176 or minor surgical procedures or diagnostic, therapeutic, or endoscopic procedures such as upper GI endoscopy,1 2 3 7 71 72 73 74 75 76 77 78 79 bronchoscopy,1 2 3 80 157 cystoscopy,1 2 7 115 157 cardiac catheterization,1 2 7 35 85 157 coronary angiography,1 50 85 157 oncology procedures,1 radiologic procedures1 (e.g., computerized tomography),1 89 or suture of lacerations.1


Some clinicians consider midazolam the benzodiazepine of choice for moderate sedation (formerly known as conscious sedation) prior to short procedures14 181 because of its relatively rapid onset2 4 7 14 74 75 79 86 178 and short duration of action,4 7 26 46 74 75 86 87 176 178 pronounced amnesic effect,7 25 73 74 75 78 79 115 178 and improved local tolerance at the site of injection2 7 14 25 74 75 76 78 79 86 87 176 177 178 compared with other currently available IV benzodiazepines.


Induction and Maintenance of Anesthesia


Induction of general anesthesia prior to administration of other anesthetic agents.1 2 3 4 7 14 25 35 70 84 87 95 99 100 101 102 103 104 105 106 107 108 125 157 Induction with midazolam provides anxiolysis, anterograde amnesia, and dose-related hypnotic effects (progressing from sedation to loss of consciousness), but not analgesia.2 4 7 70 84 86 104 177 178


An acceptable alternative to thiopental for induction of anesthesia; midazolam’s slow onset and long duration of action and variability in response relative to those of thiopental preclude it from becoming the drug of choice for induction of anesthesia in most patients, particularly outpatients and patients undergoing short surgical procedures.2 4 7 181 182


Maintenance of anesthesia during short surgical procedures,1 2 3 4 14 27 100 113 114 usually in conjunction with inhalation anesthetic agents, balanced anesthesia (e.g., nitrous oxide and oxygen), and/or opiate agonists (e.g., fentanyl).1 70 112 113 184 Should not be used alone for maintenance of anesthesia.2 27 70 184


Use for maintenance of anesthesia during relatively long surgical procedures has not been fully evaluated to date.1 3 27 70 157 181


Sedation in Critical-care Settings


Sedation of intubated and mechanically ventilated patients in a critical-care setting.1 220 221 222 223


A preferred drug for sedation of acutely agitated patients in critical-care settings because of its rapid onset and short duration of action.235


As effective as propofol and appears to have a better adverse effect profile (e.g., less hypotension) than propofol;220 221 223 however, midazolam appears to have a more variable effect on recovery of consciousness and time to recovery of function after cessation of therapy than propofol.220 223


Recommended for short-term (≤24 hours) sedation only, since the effects of the drug on awakening and the time to extubation are unpredictable when midazolam infusions are administered over longer periods (e.g., exceeding 48–72 hours).235


Insomnia


Has been used for short-term management of insomnia†.4 7 116 117 118 119 120 121 122 123


Agitation


Has been used for management of acute agitation†.53 90 146 147 148 181


Midazolam Hydrochloride Dosage and Administration


General



  • Adjust dosage according to individual requirements and response, age, body weight, physical and clinical status, underlying pathologic condition(s), type and amount of premedication or concomitant medication, and the nature and duration of the surgical or other procedure; however, individual response also may vary independent of these factors.1 3 157 163 193




  • Facilities for administration of oxygen and controlled respiration should be readily available during and immediately following IV administration.1 3 193




  • Oral solution is intended for use in monitored settings (e.g., hospital, ambulatory care settings including physician and dental offices) only; is not intended for chronic or home use.219



Administration


Administer orally,219 by IM injection, or by slow IV injection 1 2 3 4 7 14 157 193 or continuous IV infusion.1 36 90 150 181 219 Avoid intra-arterial injection or extravasation of the drug.1 Do not administer intrathecally or epidurally.1


Oral Administration


Consult manufacturer’s labeling for instruction on use of the special press-in bottle adapter and oral dispensers for administration of the oral solution.219


Administer from the individual oral dispenser directly into the child’s mouth; do not mix the oral solution with any other liquid (e.g., grapefruit juice) prior to administration.219


Effect of food on absorption of the oral solution has not been determined, but food intake generally is precluded prior to procedural sedation in pediatric patients.219


IM Administration


Administer deeply into a large muscle mass.1 3 157


IV Administration


For solution and drug compatibility, see Compatibility under Stability.


Direct IV injection should be made in incremental doses.1 3 157 163


Use of the 1-mg/mL injection is recommended to facilitate slow direct IV injection of the drug;1 193 the 1- and 5-mg/mL injections may be diluted with a compatible diluent (see Solution Compatibility under Stability) to facilitate slower injection.1


Dilution

For administration as a continuous IV infusion, dilute the 5-mg/mL injection to a concentration of 0.5 mg/mL with a compatible diluent (see Solution Compatibility under Stability).1


Rate of Administration: General

Rapid IV administration may result in respiratory depression, airway obstruction, and/or respiratory arrest.1


Rate of Administration: Pediatric Patients

IV injection for preoperative or procedural sedation: Administer IV midazolam over 2–3 minutes; wait an additional 2–3 minutes to fully evaluate the sedative effect before initiating a procedure or repeating a dose.1


Do not administer by rapid IV injection in neonates.1 (See Boxed Warning.)


Continuous IV infusion: Individualize the infusion rate.1 (See General and also Pediatric Patients: Sedation in Critical-care Settings, under Dosage and Administration.)


Rate of Administration: Adults

IV injection for procedural sedation: Administer the appropriate dose as a 1-mg/mL solution over ≥2 minutes; allow ≥2 minutes to evaluate the sedative effect.1 163 193


IV injection for induction of anesthesia: Administer the appropriate dose as a 1-mg/mL solution over 20–30 seconds; supplemental doses may be given at 2-minute intervals.1 3 157


Continuous IV infusion: Individualize the infusion rate.1 (See General and also Adults: Sedation in Critical-care Settings, under Dosage and Administration.)


Dosage


Available as midazolam hydrochloride; dosage expressed in terms of midazolam.1 3


Pediatric Patients


The depth of sedation/anxiolysis needed depends on the type of procedure being performed.1 It is vital to titrate the midazolam dose and the dose of other concomitant drugs slowly to achieve the desired clinical effect.1


Unlike adult patients, pediatric patients generally receive increments of midazolam on a mg/kg basis; calculate dosage in obese children on the basis of ideal body weight.1 219 Pediatric patients generally require higher dosages on a mg/kg basis than adults;1 patients <6 years of age generally require higher drug dosages on a mg/kg basis than older children and may require closer monitoring.1 219


It is essential to wait 2–3 minutes to fully evaluate the sedative effect before starting the procedure or administering a repeat dose; peak EEG effects are not achieved as quickly as with diazepam, since midazolam is water soluble.1


Preoperative Sedation, Anxiolysis, and Anterograde Amnesia

Oral

Children 6 months to 16 years of age: 250–500 mcg/kg as a single dose, depending on the status of the patient and the desired effect (maximum 20 mg).219


250 mcg/kg may be sufficient for children 6–16 years of age or for cooperative patients, especially if the anticipated intensity and duration of sedation is less critical.219


Younger children (e.g., 6 months to <6 years of age) and less cooperative patients may require a higher than usual dose of up to 1 mg/kg (maximum 20 mg).219


Consider an initial dose of 250 mcg/kg for patients 6 months to 16 years of age with cardiac or respiratory compromise, other higher-risk surgical patients, and those who have received concomitant opiates or other CNS depressants.219


IV

Nonintubated patients <6 months of age: Limited dosing information is available.1 Dosing recommendations are unclear because of uncertainty about when a patient transfers from a neonatal to pediatric physiology; however, titration of the dose in small increments to clinical effect and careful monitoring are essential, since patients <6 months of age are vulnerable to airway obstruction and hypoventilation.1


Children 6 months to 5 years of age: Initially, 50–100 mcg/kg; a total dose of up to 600 mcg/kg may be required to reach the desired endpoint, but total dose usually does not exceed 6 mg.1


Children 6–12 years of age: Initially, 25–50 mcg/kg; a total dose of up to 400 mcg/kg may be required to reach the desired endpoint, but total dose usually does not exceed 10 mg.1


Adolescents 12–16 years of age: Dose as adults; although some patients in this age range may require higher than recommended adult doses, total dose usually does not exceed 10 mg.1


Dosage must be reduced in pediatric patients receiving opiates or other sedatives as premedications; higher-risk or debilitated patients may require lower dosages regardless of whether premedication was administered.1


IM

Pediatric patients ≥1 month of age: 100–150 mcg/kg; doses up to 500 mcg/kg have been used for more anxious patients.1 Total dose usually does not exceed 10 mg, although this has not been systematically studied.1


If midazolam is administered with an opiate, reduce the initial dose of each drug.1


Procedural Sedation

Oral

Children 6 months to 16 years of age: 250–500 mcg/kg as a single dose, depending on the status of the patient and the desired effect (maximum 20 mg).219


250 mcg/kg may be sufficient for children 6–16 years of age or for cooperative patients, especially if the anticipated intensity and duration of sedation is less critical.219


Younger children (e.g., 6 months to <6 years of age) and less cooperative patients may require a higher than usual dose of up to 1 mg/kg (maximum 20 mg).219


Consider an initial dose of 250 mcg/kg for patients 6 months to 16 years of age with cardiac or respiratory compromise, other higher-risk surgical patients, and those who have received concomitant opiates or other CNS depressants.219


IV

Nonintubated patients <6 months of age: Limited dosing information is available.1 Dosing recommendations are unclear because of uncertainty about when a patient transfers from a neonatal to pediatric physiology; however, titration of the dose in small increments to clinical effect and careful monitoring are essential, since patients <6 months of age are vulnerable to airway obstruction and hypoventilation.1


Children 6 months to 5 years of age: Initially, 50–100 mcg/kg; a total dose of up to 600 mcg/kg may be required to reach the desired endpoint, but total dose usually does not exceed 6 mg.1


Children 6–12 years of age: Initially, 25–50 mcg/kg; a total dose of up to 400 mcg/kg may be required to reach the desired endpoint, but total dose usually does not exceed 10 mg.1


Adolescents 12–16 years of age: Dose as adults;1 some patients may require higher than recommended adult doses, but total dose usually does not exceed 10 mg.1


Dosage must be reduced in pediatric patients receiving opiates or other sedatives as premedications; higher-risk or debilitated patients may require lower dosages regardless of whether premedication was administered.1


IM

Children ≥1 month of age: 100–150 mcg/kg; doses up to 500 mcg/kg have been used for more anxious patients.1 Total dose usually does not exceed 10 mg, although this has not been systematically studied.1


If midazolam is administered with an opiate, reduce the initial dose of each drug.1


Sedation in Critical-care Settings

Neonates

IV

IV loading doses should not be used in neonates; rather, the infusion may be administered more rapidly for the first several hours to establish therapeutic plasma drug concentrations.1


Preterm neonates (<32 weeks’ gestation): Initially, 30 mcg/kg per hour (0.5 mcg/kg per minute).1


Term neonates (≥32 weeks’ gestation): Initially, 60 mcg/kg per hour (1 mcg/kg per minute).1


Reassess the infusion rate carefully and frequently, particularly after approximately the first 24 hours, to administer the lowest possible effective dosage and to reduce the potential for drug accumulation.1 This is particularly important because of the potential for adverse effects related to benzyl alcohol metabolism.1 (See Pediatric Use under Cautions.)


Non-neonatal Pediatric Patients (Intubated)

IV

Initially, 50–200 mcg/kg as a loading dose, followed by a continuous IV infusion initiated at a rate of 60–120 mcg/kg per hour (1–2 mcg/kg per minute) to maintain the clinical effect.1


Increase or decrease the infusion rate as required, generally by 25% of the initial or subsequent infusion rate, or administer supplemental IV doses to increase or maintain the desired effect.1 Perform frequent patient assessments at regular intervals using standard pain/sedation scales.1


Midazolam infusions have been used in children whose trachea was intubated but who were allowed to breathe spontaneously; however, assisted ventilation is recommended in those who are receiving other CNS depressants (e.g., opiates).1


In hemodynamically compromised children, initiate therapy by titrating the usual loading dose in small increments; monitor the patient closely for hemodynamic instability (e.g., hypotension).1


Adults


Preoperative Sedation, Anxiolysis, and Anterograde Amnesia

IM

70–80 mcg/kg (about 5 mg) administered approximately 30–60 minutes prior to surgery.1 3 14 180 181 If administered concomitantly with an opiate agonist or other CNS depressant, the midazolam dosage must be individualized and reduced.1


Procedural Sedation

IV

Initial dose of ≤2.5 mg in healthy adults <60 years of age; some patients may respond to as little as 1 mg.1 193 Total dose of ≤5 mg generally is adequate.1


If a thorough clinical evaluation clearly indicates a need for additional doses to maintain the desired level of sedation, administer additional doses in increments of approximately 25% of the initial dose.1 3


A total dose up to 200 mcg/kg has been used rarely, particularly if an opiate agonist was not used concomitantly;3 157 191 192 avoid such doses, if possible.180


Some clinicians recommend initiating dosing with 0.5–2 mg and repeating doses, as necessary, at 2- to 3-minute intervals up to a total dose of 100–150 mcg/kg.14 181


When used concomitantly with an opiate agonist or other CNS depressant, reduce midazolam dosage by about 30%.1 3 14 157


Induction and Maintenance of Anesthesia

IV

Individual response is variable, especially when opiate agonist premedication is not used; therefore, titrate dosage carefully to the desired clinical effect, taking into consideration the patient’s age and clinical status.1 2 3 70


When used prior to other anesthetic agents for the induction of general anesthesia,1 3 the initial dose of each of these agents may be substantially reduced, in some instances to as low as 25% of the usual initial dose of the individual agents.1


Without Opiate Premedication

IV

Initial dose of 300–350 mcg/kg administered IV over 20–30 seconds in patients <55 years of age; allow approximately 2 minutes for clinical effect.1 3 157 180 Alternatively, some clinicians recommend an initial dose of 200 mcg/kg.14 144 181


Supplemental doses of about 25% of the initial dose may be given as necessary to complete induction or for maintenance of sedation or anesthesia.1 3 14 157 Alternatively, induction of anesthesia may be completed with inhalation agents.1 3 157


Total IV induction doses of up to 600 mcg/kg may be required in some resistant patients, but such doses may prolong recovery from anesthesia.1 3 4 100 157


With Opiate or Sedative Premedication

IV

Initial dose of 150–350 mcg/kg as an induction dose in patients <55 years of age.1 3 157 Usual induction dose is 250 mcg/kg administered IV over 20–30 seconds; allow approximately 2 minutes for clinical effects.1 3 157


For maintenance of anesthesia (as a component of balanced anesthesia) during short surgical procedures: Following premedication with an opiate agonist,1 3 administer in incremental IV doses of approximately 25% of the initial induction dose when lightening of anesthesia is evident.1 3 Repeat as necessary according to patient’s response to maintain the required level of anesthesia.1 3


Sedation in Critical-care Settings

IV

If a loading dose is necessary to initiate sedation rapidly, 10–50 mcg/kg (approximately 0.5–4 mg) administered slowly or infused over several minutes.1 Repeat this dose at 10- to 15-minute intervals until adequate sedation is achieved.1 Usual initial infusion rate for maintenance of sedation is 20–100 mcg/kg per hour (approximately 1–7 mg per hour).1 Higher loading doses or maintenance infusion rates occasionally may be required.1


In patients with residual effects from anesthetic agents or in those currently receiving other sedatives or opiates, use the lowest recommended dosage.1


Infuse at the lowest rate that produces the desired level of sedation.1 Assess sedation at regular intervals and adjust the infusion rate up or down by 25–50% of the initial infusion rate to ensure adequate titration of the sedation level.1 Larger adjustments or even a small, incremental dose may be necessary if rapid changes in the level of sedation are required.1 Decrease infusion rate by 10–25% every few hours to find the minimum effective infusion rate.1


Consider administering an opiate concomitantly in patients experiencing agitation, hypertension, or tachycardia in response to noxious stimuli but who otherwise are adequately sedated.1 Addition of an opiate generally will reduce the minimum effective midazolam infusion rate.1


Prescribing Limits


Pediatric Patients


Preoperative Sedation, Anxiolysis, and Anterograde Amnesia or Procedural Sedation

Oral

Children 6 months to 16 years of age: Maximum 20 mg.219


IV

Manufacturer states that the total dose usually does not exceed 6 mg in pediatric patients 6 months to 5 years of age or 10 mg in those 6–16 years of age.1


IM

Manufacturer states that the total dose usually does not exceed 10 mg in pediatric patients ≥1 month of age, although this has not been systematically studied.1


Procedural Sedation

IV

Manufacturer states that the total dose usually does not exceed 6 mg in pediatric patients 6 months to 5 years of age or 10 mg in those 6–16 years of age.1


Adults


Procedural Sedation

IV

Initial dose for sedation should not exceed 2.5 mg.1


Special Populations


Renal Impairment


Use with caution and individualize dosage carefully.1 2 4 7 31 33 34 42 70 163 (See Renal Impairment under Cautions.)


CHF


Use with caution and individualize dosage carefully.1 3 35 50 163 (See Special Populations under Pharmacokinetics and also Other Populations under Dosage and Administration.)


Geriatric Patients


Reduce initial dose, since some degree of impairment in 1 or more organ systems frequently is present.1 3 157 163 193 Dosage requirements in this age group generally appear to decrease with increasing age;1 163 consider the possibility of profound and/or prolonged effects in older and/or debilitated patients.1 Low doses usually are required when midazolam is administered with or without premedication.1 3 157 163 193


Dosage titration should be more gradual in patients ≥60 years of age receiving midazolam for procedural sedation and in those ≥55 years of age receiving the drug for induction of anesthesia.1 157 163 180


Use the smallest effective dose.1 3 Excessive doses or rapid or single large IV injections may result in respiratory depression and/or arrest.1 3 157 163 193


Preoperative Sedation, Anxiolysis, and Anterograde Amnesia in Patients ≥60 Years of Age

IM: In patients ≥60 years of age who did not receive concomitant opiate agonist therapy, doses of 2–3 mg (20–50 mcg/kg) have produced adequate preoperative sedation;1 1 mg may be sufficient in some geriatric patients if the anticipated intensity and duration of sedation is less critical.1


Procedural Sedation in Patients ≥60 Years of Age

IV: Initial dose of ≤1.5 mg 1 193 over ≥2 minutes; wait ≥2 minutes to fully evaluate the clinical response.1 If further sedation is required, the dosage may be further titrated in small increments (≤1 mg) of the initial dose to the desired effect (e.g., onset of slurred speech).1 Total dose of ≤3.5 mg usually is adequate.1


If a thorough clinical evaluation clearly indicates a need for additional doses to maintain the desired level of sedation, administer additional doses that are1 3 reduced by ≥25%.14


When used concomitantly with an opiate or other CNS depressant, reduce midazolam dosage to about 50% of that used in young, unpremedicated adults.1


Induction and Maintenance of Anesthesia in Patients ≥55 Years of Age

IV: Manufacturer recommends an initial IV induction dose of 300 mcg/kg if premedication has not been given.1 3 157


If premedication has been given, manufacturer recommends an initial induction dose of 200 mcg/kg if the patient is a good risk (e.g., ASA I and II) surgical patient.1 3


Other Populations


Preoperative Sedation, Anxiolysis, and Anterograde Amnesia in Patients with COPD or Other Higher-risk Surgical Patients

IM: Individualize and reduce dosage in patients with COPD and in other higher-risk surgical patients.1


Procedural Sedation in Chronically Ill or Debilitated Patients

IV: Smaller increments in dosage and slower rate of injection recommended in patients with chronic debilitating illnesses (e.g., CHF) or decreased pulmonary reserve because of the increased risk of underventilation or apnea and because the peak drug effect may occur later.1 3 157 163 180 193


Administer initial dose of ≤1.5 mg 1 193 over ≥2 minutes; wait ≥2 minutes to fully evaluate the clinical response.1 If further sedation is required, the dosage may be further titrated in small increments (≤1 mg) of the initial dose to the desired effect (e.g., onset of slurred speech).1 Total dose of ≤3.5 mg usually is adequate.1


If a thorough clinical evaluation clearly indicates a need for additional doses to maintain the desired level of sedation, administer additional doses that are1 3 reduced by ≥25%.14


When used concomitantly with an opiate or other CNS depressant, reduce midazolam dosage to about 50% of that used in young, unpremedicated adults.1


Induction and Maintenance of Anesthesia in Patients with Severe Systemic Disease or Other Debilitation

IV: Unpremedicated patients: Initial dose of 200–250 mcg/kg usually is adequate; doses as low as 150 mcg/kg may be adequate for induction in some patients.1 3 157


Premedicated patients: Doses as low as 150 mcg/kg may be adequate for induction in some patients.1 3 157


Cautions for Midazolam Hydrochloride


Contraindications



  • Known hypersensitivity to midazolam or any ingredient in the formulation; oral solution contraindicated in patients with allergies to cherries.1 219




  • Acute angle-closure glaucoma (but may be administered to patients with open-angle glaucoma who are receiving appropriate therapy).1




  • Midazolam hydrochloride injection contains benzyl alcohol and is not intended for intrathecal or epidural administration.1



Warnings/Precautions


Warnings


Respiratory and Cardiovascular Effects

Possible serious and occasionally fatal adverse effects, including respiratory depression, airway obstruction, oxygen desaturation, apnea, respiratory arrest, and/or cardiac arrest,1 2 37 137 139 157 163 175 193 particularly in patients receiving midazolam concomitantly with other CNS depressants1 250 and in those undergoing procedures involving the airway without the protective effect of an endotracheal tube, in geriatric or severely ill patients, or in patients with limited pulmonary reserve or unstable cardiovascular status, or if the drug is administered IV too rapidly.1


Possible hypotensive episodes requiring treatment during or following diagnostic or surgical manipulation.1 Concomitant administration of an opiate agonist may increase the risk of severe hypotension.1 4 14 112


Do not administer parenterally to patients with shock, those who are comatose, or those with acute alcohol intoxication and accompanying depression of vital signs.1 Exercise caution if administered IV to patients with uncompensated acute illnesses, including severe fluid or electrolyte imbalances.1


Slow administration and individualized titration of dosage is required.1


Administer orally or IV only in settings in which continuous monitoring of respiratory and cardiac function (i.e., pulse oximetry) is possible.1 250 Potential for hypoxia and/or cardiac arrest if early signs of hypoventilation, airway obstruction, or apnea are not corrected immediately.1 Monitoring of vital signs should continue during recovery period.1


Should be administered as an induction agent only by individuals who are experienced in the use of general anesthesia.1 163 193 219


Should be used for procedural sedation only in the presence of personnel experienced in early detection of underventilation, maintenance of an adequate airway, and respiratory support.1 163 193 219 When the complexity of the procedure prohibits adequate monitoring by the attending clinician, additional personnel competent in monitoring and managing potential complications should be in attendance.1 163 175 For deeply sedated pediatric patients, an individual other than the clinician performing the procedure should be dedicated to monitoring the patient throughout the procedure.1 250


Facilities, age- and size-appropriate equipment for bag/mask/valve ventilation and intubation, drugs, skilled personnel necessary for ventilation an